

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:	)	
	)	
Ayako Hashimoto <i>et al.</i>	)	Group Art Unit: 1625
	)	
Application No.: 10/587,045	)	
	)	Examiner: Celia C. Chang
Filed: July 24, 2006	)	
	)	
For: PHARMACEUTICAL	)	
COMPOSITION FOR PROMOTING	)	Confirmation No.: 8787
ANGIOGENESIS	)	

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**REPLY AFTER FINAL**

Applicants reply to the final Office Action dated August 17, 2010 ("Office Action"), the period for response having been extended to January 17, 2011 (a federal holiday), by a request for extension of two months and fee payment filed concurrently herewith.

**Remarks** begin at page 3 of this paper.

**Attachments** to this paper include:

- (1) Gowda, R.M. et al., "Reversible Myocardial Dysfunction: Basics and Evaluation," *Int. J. Cardiol.* (2004) vol. 97, pp. 349-353.
- (2) Sasayama, S. et al., "Recent Insights Into Coronary Collateral Circulation," *J. Am. Heart Assoc.* (1992) vol. 85, pp. 1197-1204.
- (3) Freedman, S.B. et al., "Therapeutic Angiogenesis for Ischemic Cardiovascular Disease," *J. Mol. Cell Cardiol.* (2001) vol. 33, pp. 379-393.
- (4) Ye, L. et al., "Angiopoietin-1 for Myocardial Angiogenesis: A Comparison Between Delivery Strategies," *Eur. J. Heart Failure* (2007) vol. 9, pp. 458-465.

(5) Pan, S.L. et al., "Identification of Apoptotic and Antiangiogenic Activities of Terazosin in Human Prostate Cancer and Endothelial Cells," *J. Urology* (2003) vol. 169, pp. 724-729.

(6) Keledjian, K. and Kyprianou, N., "Anoikis Induction by Quinazoline Based  $\alpha 1$ -Adrenoceptor Antagonists in Prostate Cancer Cells: Antagonistic Effect of BCL-2," *J. Urology* (2003) vol. 169, pp. 1150-1156.

(7) Orito, K. et al., " $\alpha_2$ -Adrenoceptor Antagonist Properties of OPC-28326, a Novel Selective Peripheral Vasodilator," *Brit. J. Pharmacol.* (2001) vol. 134, pp. 763-770.